Introduction
The tumour suppressor gene p53 has been extensively studied because of the high frequency of p53 mutations in human cancers. In normal cells p53 is activated in response to dierent stimuli (DNA damage, hyperproliferative signals) and transactivates eector genes involved in cell cycle arrest (p21, GADD45) and in the induction of programmed cell death (PIG3, Bax, p53AIP). Tumour derived p53 mutants usually lack transcriptional activity. However, some mutants retain the ability to transactivate a subset of p53 target genes. These mutants can induce p21 waf1 -mediated G1 arrest, but not Bax-mediated apoptosis Rowan et al., 1996) . The likely basis for this dierence is that these mutants have a modestly reduced anity for DNA, allowing them to bind to promoters with high anity p53 binding sites, as in the p21 promoter, but not to promoters with low anity sites, as in the Bax promoter. Using simple yeast transcription assays, the same mutants have been shown to be competent for transactivation of reporter genes containing the p53 binding sites from the p21 but not the Bax promoters (Flaman et al., 1998) . Thus, yeast transcription assays can be used to predict the transcriptional behaviour of a mutant in higher eukaryotes. In a more recent study, approximately 20% of the mutants analysed were found to be discriminant mutants: they were able to transactivate a reporter gene under control of a p21 response element while they were unable to transactivate the same reporter gene under control of the response elements of two pro-apoptotic genes (Bax, PIG3) (Campomenosi et al., 2001) . Furthermore, many mutants showed a temperature sensitive phenotype, indicative of a¯exible protein structure (Di Como and Prives, 1999; Campomenosi et al., 2001) .
p53 mutants dier from each other not only in their ability to discriminate between sequences but also in their ability to abrogate transactivation by wild type p53, (i.e. their dominant negative potential). Since p53 is active as a tetramer, inhibition of wild type p53 is thought to occur through tetramerization with mutant p53 in heterozygous cells. Alternatively, over-expressed p53 mutants can inhibit transcriptional activity of wild type p53, through depletion of speci®c cofactors rather than hetero-oligomerization (JoÄ ers et al., 1998) . However, the extent to which p53 mutants really do abrogate wild type p53 function in the heterozygous state is controversial and depends on the particular assay employed (Waterman et al., 1996; Bargonetti et al., 1992; Kern et al., 1992; Frebourg et al., 1994) . In yeast assays, where stable and equal expression of mutant and wild type protein can easily be achieved, the analysis of many p53 alleles associated with tumours revealed that many mutants are recessive (Brachmann et al., 1996; Inga et al., 1997a) .
Dominance over wild type can play a role in carcinogenesis only during the period in which both the mutant and wild type alleles are co-expressed in the same cell. This period can be as long as 20 years and it characterizes tumour development, either following a somatic mutagenic event, or from birth in Li ± Fraumeni syndrome. If the level of p53 activity during the heterozygous stage in tumour development is important, one would predict that dominant negative p53 mutants should accelerate the development of tumours. A result compatible with this prediction was obtained by Marutani et al. (1999) who showed that dominant negative p53 mutants are associated with earlier onset of brain tumours.
Within the framework of a more general attempt to classify p53 mutants into functional categories we sought to determine: (i) which p53 mutants are dominant; (ii) what features characterize dominant mutants; and (iii) whether the dominant potential of a mutant is target gene speci®c. For this purpose 71 p53 mutants obtained in previous works (Inga et al., 1997b; Kelly et al., 1999; Monti et al., 2000) were examined in yeast for dominance over wild type under conditions of equal expression (Inga et al., 1997a) . In this assay, wild type p53 is expressed from a TRP1 vector, p53 mutants are expressed from a LEU2 vector, and net transcriptional activity is scored using an ADE2 reporter containing the p53 binding site identi®ed in the ribosomal gene cluster (3xRGC, reporter strain yIG397). Recessive mutants give white colonies, and dominant mutants give pink or red colonies. To determine whether the ability of p53 mutants to inhibit wild type p53 is target gene speci®c, the dominance towards p21, bax and PIG3 binding sites was examined. Approximately 40% of the 45 mutants examined were dominant for the p21 (17/45) or PIG3 (20/45) responsive elements and 71% (32/45) were dominant for the bax responsive element.
Results

Identification of dominant p53 alleles towards the RGC responsive element
Among the panel of 71 mutants examined in our study, 64 had single amino acid substitutions, 57 of which lie within the core p53 DNA binding domain. The remaining seven nonsense mutations were spread throughout the open reading frame (Table 1) . Nearly 30% (20/71) of the mutants were classi®ed as dominant for the RGC responsive element in yIG397. All dominant mutants had missense mutations that lay in the core p53 DNA binding domain (20/57, 35%). All nonsense mutants were recessive, suggesting that the tetramerization domain is necessary for a mutant to abrogate wild type function. Table 1 lists the structural elements containing the residue (nomenclature according to Cho et al., 1994) , the evolutionary conservation of the residue (Soussi and May, 1996) , and whether the residue is a hotspot for mutations in tumours (Walker et al., 1999) .
Dominant mutants appeared to cluster in speci®c protein structures, namely the two alpha helices (H1 (four mutants) and H2 (®ve mutants), and the L3 loop (eight mutants). Two mutants involved amino acids in the S10 strand which is part of the loop-sheet-helix motif (LSH, L1/S2-S22'/S10/H2) that sits in the major groove of the DNA. None of the mutants located in L1 was dominant. Only one dominant mutant was not located near the DNA binding surface: L 257 P in the S9 beta strand. Thus, nearly all of the dominant mutants (19/20) occurred near the DNA binding surface. A total of 30 mutations were analysed in the DNA binding surface, while 27 mutations were analysed in other regions within the core binding domain. The clustering of dominant mutants near the DNA binding surface is highly signi®cant (19/30 vs 1/27, P50.0001, Fisher's exact test). These results complement those obtained by Brachmann et al. (1996) who suggested that dominant negative p53 mutations speci®cally hit functionally important amino acids. Furthermore, the average evolutionary conservation of the amino acids mutated in recessive mutants is signi®cantly lower than that of dominant mutants (P50.005, Mann ± Whitney test). Compared to dominant mutants, recessive mutants frequently aect coldspot in tumours (see no hotspot in Table 1 ; 21 out 37 in recessive mutants; three out of 20 in dominant mutants: P50.005, Fisher's exact test).
We conclude that dominant mutants preferentially involved highly conserved amino acids which are frequently mutated in tumours and lie near the DNA binding surface of the protein.
Comparison of different substitutions at the same codon
In the panel of mutants tested there were many mutant sites for which two or three amino acid substitutions at the same codon were identi®ed (P 98 H, S and L; S 99 Y and F; Y 126 D, and S; P 151 S, and H; P 152 L, and T; P 177 S, F, and H; R 181 G, and H; S 241 T, and F; G 245 S, and D; D 259 N and V; G 266 R, and E; G 279 R, V, and E; E 281 N and E; E 286K, and G). In all cases (14/14) mutants with dierent amino acid substitutions at the same codon showed identical dominance potential, i.e. if one amino acid substitution was dominant the other was dominant too. Our results suggest that, in general, the location more than the amino acid substitution determines the ability of a mutant to be dominant.
Dominance is responsive element-specific
The consensus p53 binding sequence is highly degenerate (5'-PuPuPuC(A/T)(T/A)GPyPyPy-3') so that there are dierences in the binding of p53 to dierent target genes. This explains dierences in the activity of speci®c mutants on speci®c target genes (Flaman et al., 1998; Di Como and Prives, 1999; Robert et al., 2000; Campomenosi et al., 2001) . Assuming that dominance requires tetramerization of mutant with wild type proteins, alteration of the ability of the mixed tetramer to bind to DNA would depend on binding ability to individual targets (Figure 1 ). In order to explore this issue, we tested 45 mutants (41 mutants had missense mutations in the DNA binding domain, two had missense mutations outside the DNA binding domain and two had nonsense mutations) for transdominance on promoters containing three dierent p53 responsive elements. The reporter strains (yPH-p21, yPH-bax and yPH-PIG3) express ADE2 from promoters containing the following sequences: p21, 5'-GAACATGTCCCAA-CATGTTG-3', bax, 5'-TCACAAGTTAGAGACAAG-CCTGGGCGTGGGCTATATTG-3', PIG3, 5'-CAGC-TTGCCCACCCATGCTC-3' (Flaman et al., 1998; Robert et al., 2000) .
The number of mutants scored as dominant is dierent for the three strains (Table 2) . In other words, a hierarchy of dominance was detected. All the mutants scored as dominant in yPH-p21 were dominant in the Per cent of species in which the speci®c codon was identical (data from Soussi and May, 1996 To rule out dierences in protein stability between wild type and mutant p53 alleles in yeast and changes in stability among the dierent yeast strains as a cause for the dierences in dominance potential and activity, Western blotting was performed. This analysis showed that the protein level of mutants and wild type was similar in every strain (Figure 2 and data not shown). We conclude that dierences in phenotype were not due to dierences in protein level.
BRCA-associated mutants
A novel class of p53 mutants found in BRCAassociated tumours has been described recently (Smith et al., 1999) . Four of these mutants (150I, 199R, 202S, 215C) behave like wild type p53 in growth suppression, transcription and apoptosis assays, but show gain of function in transformation assays. These mutants are also indistinguishable from wild type p53 in the yIG397, yPH-bax, yPH-p21 and yPH-PIG3 strains (Campomenosi et al., 2001) . We tested 12 mutants found in BRCA-associated tumours for dominance (Table 3) . Unlike the BRCA-derived mutants that are found in sporadic tumours, the four`transformation only' mutants were recessive in every strain.
Discussion
The present study highlights some features of p53 mutants which display dominance, and shows that dominance is target gene speci®c. Based on our results we predict that p53-dependent transactivation of the Bax gene will be particularly sensitive to dominant negative inhibition by p53 mutants. This result is in keeping with a recent study by Aurelio et al. (2000) , who used a bidirectional expression vector that allows equal transcription of exogenous wild type and mutant p53 in a null cell line. They found that all seven mutants analysed were recessive for p21 induction but dominant for Bax induction. In contrast, the authors claim that only three (245C, 248W, 273H) out of seven mutants exerted extremely clear dominant-negative eect on apoptosis (Table 3 in Aurelio et al., 2000) . Three other mutants showed a less clear, but statistically signi®cant, eect on apoptosis. Interestingly, our results with 248W (Table 3 of the present study) in yeast are consistent with those reported by Aurelio et al. (2000) in two dierent cell lines. We studied two mutants at the same codon but with dierent amino acid substitutions (245S and 245D) with respect to the one studied by Aurelio et al. (2000) . Glycine 245 is a critical residue for overall structure of p53 because it allows the L3 loop to assume a conformation that will not be favoured with an aminoacid containing a side chain (Cho et al., 1994) . This means that every amino acid substitution at such position should behave similarly. Consistent with this prediction, we observed that both mutants (245S and 245D) in yeast behaved similarly as the 245C does in mammalian cells.
What features distinguish dominant from recessive mutants? Seventeen mutants were dominant in every Per cent of species in which the speci®c codon was identical (data from Soussi and May, 1996) . c Hotspot codon for mutation; (de®nition of the levels of statistical signi®cance, Walker et al., 1999). Mutant co-expressed with wild type p53 generating white (7), pink (+) or red (++) Leu+Trp+colonies were classi®ed as recessive (7) or dominant (+;++), respectively. NA, Not Applicable. *Amino acid substitution never found mutated in human tumours or cell lines (Hernandez-Boussard et al., 1999: IARC database http://www.iarc.fr/p53/homepage.htm). e Discriminant mutant (see Campomenosi et al., 2001) Oncogene Promoter selective dominance of p53 mutants P Monti et al reporter strain. Two features characterize these mutants: (i) they have a single amino acid substitution that lies in the H1, L3, LSH or H2 structures and (ii) when expressed alone in the dierent strains they were neither temperature sensitive nor able to discriminate between dierent response elements (Campomenosi et al., 2001) . The fact that L1 and L2 rarely harbour dominant mutations presumably re¯ects their location in¯exible loops of the protein. Nine mutants appear always recessive. Most of them (8/13, 62%) were able to discriminate between dierent responsive elements for transactivation of the reporter gene (Campomenosi et al., 2001) . Fifteen mutants were dominant depending on the responsive element. Six of them were discriminant mutants in simple transformation, i.e. they generate white colonies in yPH-p21 while generating pink/red colonies in yPH-bax, yPH-PIG3 strains, and were obviously classi®ed as recessive in yPH-p21. The remaining nine mutants were dominant in yPH-bax while being recessive in yPH-p21 or yPH-PIG3 despite the fact that when expressed alone the mutant generated red colonies in all strains.
In most cases, mutants with dierent amino acid substitutions at the same codon showed identical dominance potential: if one amino acid substitution was dominant then the other was dominant too, and they had the same response element pattern. There were two exceptions. Mutant 279E was dominant while 279R and 279V were recessive in yPH-p21. This was expected since 279R and 279V, in contrast to 279E, are still able to transactivate a reporter gene under control of a p21 response element in single transactivation assay (Campomenosi et al., 2001) . Similar results were obtained with 259V and 259N, i.e. the former being dominant only in yPH-Bax, the latter being always recessive. It is worth noting that 259N is also a discriminant mutant retaining function only towards the p21 responsive element. Since heterotetramers are likely to be the same when mutants are expressed in the PIG3 and bax isogenic reporter strains, these results suggest that the same heterotetramer has per se dierent anities for the two dierent response elements. Our results suggest that, in general, the location of an amino acid is more important than the amino acid substitution in determining whether a mutant is dominant. We did not exhaustively test all the possible substitutions at a particular codon. However, complete testing of substitutions at codon 175 showed that multiple dierent phenotypes can be seen for a particular mutant, although not all of these changes are selected in tumours (Ory et al., 1994 ; Per cent of species in which the speci®c codon was identical (data from Soussi and May, 1996 Promoter selective dominance of p53 mutants P Monti et al Blagosklonny et al., 2001 ). It appears that the more residual transactivation activity a mutant has for a speci®c response element, the less likely it will behave in a dominant fashion on the same response element. In keeping with this rule, we invariably found that BRCA-associated p53 mutants that behaved like wildtype p53 in transcription assays were always recessive in yeast. This suggests that these mutants do not promote transformation in vitro by inactivating the transactivating function of the endogenous wild type p53. However, based on results with single response elements, the fact that among a panel of mutants that completely lack transactivation capability (red colonies in yeast assay) only some mutants are dominant over wild type suggests that lack of transactivation capability is a prerequisite but it is not sucient to predict dominance. The mechanism through which dominance appears to be response element speci®c is at present unknown. However, it is possible to hypothesize that the reason resides in the anity of p53 towards each dierent responsive elements. Indeed, responsive elements with low anity to wild type p53 (e.g. bax) will be more sensitive to the dominant eects of mutants since the already sub-optimal interaction of the wild type p53 homotetramers is likely to be aected even by moderate conformation distortions caused by mutant p53 alleles in heterotetramers. We previously demonstrated that p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 response elements (Campomenosi et al., 2001) , suggesting that tumours expressing only a p53 mutant allele lack more often the ability to activate some apoptotic pathways than to induce cell cycle arrest. Here we demonstrate that, even when heterozygous, inactivation of some apoptotic pathways by dominant mutants would be more frequent than inactivation of cell cycle arrest. This is consistent with decreased ability to induce apoptosis being an important determinant during tumour development.
The notion that not all p53 mutants are functionally equivalent is well documented and probably underestimated due to the relative low number of p53 response elements tested among the response elements known to date. This functional heterogeneity represents a key point in view of a cancer therapy based on p53 status. It is sure that rational selection of patients for such therapy will pose a major clinical challenge, and that sequencing alone will only provide guidance when the properties of the mutants are known. It is therefore strongly recommended the creation of a functional database for p53 mutants.
Materials and methods
Strains, vectors and media
S cerevisiae haploid strains yIG397 [3xRGC : : pCYC1 : : ADE2] (Inga et al., 1997a) , yPH-p21 (p21 : : pCYC1 : : ADE2; the p21 p53 binding site is a 20 mer sequence found 2.4 kb upstream of the p21 promoter: 5'-GAACATGTCCCAA-CATGTTG-3'), yPH-bax (bax : : pCYC1 : : ADE2; the bax p53 binding site is a 39 mer sequence found ± 113 to ± 77 from start site of transcription: 5'-TCACAAGTTAGAGA-CAAGCCTGGGCGTGGGCTATATTG-3') (Flaman et al., 1998) and yPH-PIG3 (PIG3 : : pCYC1 : : ADE2; the PIG3 p53 binding site is a 20 mer sequence found 328 ± 308 bp upstream of the PIG3 promoter: 5'-CAGCTTGCCCACC-CATGCTC-3') (Robert et al., 2000) were transformed with the indicated plasmids. pLS76 (CEN6/ARS4, LEU2) and pTS76 (CEN6/ARS4, TRP1) yeast vectors expressing the p53 cDNA under an ADH1 constitutive promoter, diers only for the selection marker and thus permit the selection of double transformants. pTS76 was used to express wild type p53, while dierent p53 mutants were expressed from pLS76 vectors.
Analysis of the dominant potential of specific p53 mutants
The haploid strains (yIG397, yPH-21, yPH-bax, yPH-PIG3) containing the ADE2 reporter gene under p53 control, were transfected with equimolar amounts of both vectors (pLS76, pTS76) by the LiAC method. Double transformants were selected on minimal plates lacking leucine and tryptophan but containing sucient adenine (5 mg l 71 ) for adenine auxotrophs to grow and turn red. Double transformant clones (Leu + , Trp + ) giving rise to white (Ade + ) or pink/red (Ade -) colonies were interpreted as expressing recessive or dominant mutations, respectively (Figure 1 ). Generally, more than 100 independent transformants were analysed and their phenotype was invariably homogeneous.
Analysis of p53 protein levels
In order to determine if the dierences in transactivation activity and dominance potential shown by some mutant alleles in the dierent strains could be attributable to dierent p53 expression levels, Western blot analysis was performed. Yeast protein extracts were prepared as follows. Colonies from appropriate plates, obtained as described in the previous section, were grown in YPDA medium and harvested at OD 595 0.7 ± 0.9. All subsequent steps were performed on ice. Cells were washed in TEN buer (100 mM NaCl, 50 mM Tris pH 8, 5 mM Na 2 EDTA) and lyzed in Lysis buer (100 mM NaCl, 20 mM Tris pH 7.2, 5 mM Na 2 EDTA, 2 mM DTT, 0.1% NP40, 10% glycerol) supplemented with protein inhibitors (PMSF, aprotinin, leupeptin, benzamidine), adding 1 vol sterile glass beads and vortexing 5640 min. Lysates were transferred to clean tubes and centrifuged. Cleared lysates were aliquoted, immediately frozen in liquid nitrogen and stored at 7808C until needed. Total protein concentration was evaluated using Biorad protein assay kit (Biorad, Milan) and by SDS ± PAGE. Eight mg total protein were loaded on 10% acrylamide gels for total protein visualization and for actin detection (used to con®rm loading of the same quantity of protein for all samples tested), while 1 mg total protein was used to detect p53 protein, due to the relatively high levels of expression from the ADH1 constitutive promoter. SDS ± PAGE and Western blotting were performed by standard methods. Mouse antihuman actin IgM (Amersham, Milan, Italy) at 1 : 7000 dilution and a mix of DO7 and pAb1801 anti p53 antibodies (generous gift of Dr B Vojtesek), each at 1 : 2000 dilution were used as primary antibodies. Peroxidase conjugated rabbit antimouse immunoglobulin (Dako, Glostrup, Denmark) at a 1 : 1500 dilution was used as secondary antibody. All antibody dilutions were prepared in 1% low fat milk in phosphate buered saline 0.1% Tween 20 (PBST).
Washes were performed in PBST or PBS. Detection was performed using Amersham ECL system (Amersham, Milan, Italy).
